Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
3,567,572
-
Share change
-
+20,133
-
Total reported value
-
$4,870,303
-
Put/Call ratio
-
20%
-
Price per share
-
$1.37
-
Number of holders
-
27
-
Value change
-
+$111,553
-
Number of buys
-
12
-
Number of sells
-
7
Institutional Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q4 2022
As of 31 Dec 2022,
Protalix BioTherapeutics, Inc. - COM (PLX) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,567,572 shares.
The largest 10 holders included
HIGHBRIDGE CAPITAL MANAGEMENT LLC, MEITAV DASH INVESTMENTS LTD, RENAISSANCE TECHNOLOGIES LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, CITADEL ADVISORS LLC, BlackRock Inc., JANE STREET GROUP, LLC, COMMONWEALTH EQUITY SERVICES, LLC, CIBC WORLD MARKET INC., and IHT Wealth Management, LLC.
This page lists
26
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.